Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $680,852 | $464,370 | $249,132 | $81,708 |
| % Growth | 46.6% | 86.4% | 204.9% | – |
| Cost of Goods Sold | $56,963 | $33,745 | $20,443 | $8,035 |
| Gross Profit | $623,889 | $430,625 | $228,689 | $73,673 |
| % Margin | 91.6% | 92.7% | 91.8% | 90.2% |
| R&D Expenses | $236,121 | $180,142 | $134,715 | $88,846 |
| G&A Expenses | $0 | $317,664 | $272,982 | $190,111 |
| SG&A Expenses | $504,489 | $409,864 | $358,782 | $272,611 |
| Sales & Mktg Exp. | $0 | $92,200 | $85,800 | $82,500 |
| Other Operating Expenses | $0 | $0 | -$1,182 | -$2,095 |
| Operating Expenses | $740,610 | $590,006 | $492,315 | $359,361 |
| Operating Income | -$116,721 | -$159,381 | -$263,626 | -$285,688 |
| % Margin | -17.1% | -34.3% | -105.8% | -349.6% |
| Other Income/Exp. Net | $42,518 | $20,343 | $7,376 | $1,568 |
| Pre-Tax Income | -$74,203 | -$139,038 | -$256,250 | -$284,120 |
| Tax Expense | $473 | $636 | $6 | $6 |
| Net Income | -$74,676 | -$139,674 | -$256,256 | -$284,126 |
| % Margin | -11% | -30.1% | -102.9% | -347.7% |
| EPS | -0.72 | -1.46 | -2.72 | -3.5 |
| % Growth | 50.7% | 46.3% | 22.3% | – |
| EPS Diluted | -0.72 | -1.46 | -2.72 | -3.5 |
| Weighted Avg Shares Out | 103,131 | 95,882 | 94,047 | 81,253 |
| Weighted Avg Shares Out Dil | 103,131 | 95,882 | 94,047 | 81,253 |
| Supplemental Information | – | – | – | – |
| Interest Income | $42,518 | $20,343 | $7,376 | $1,568 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $528 | $656 | $533 |
| EBITDA | -$116,721 | -$158,853 | -$262,970 | -$285,155 |
| % Margin | -17.1% | -34.2% | -105.6% | -349% |